Table 2 Frequencies of different types of cutaneous adverse events per DMT
Disease-modifying therapy for MS | |||||
|---|---|---|---|---|---|
GA (n = 44) | SC IFN-β-1b (n = 60) | SC IFN-β-1a (n = 66) | IM IFN-β-1a (n = 59) | Total group (n = 229) | |
Erythema | 20 (46%) | 39 (65%) | 52 (79%) | 11 (19%) | 156 (68%) |
Lipoatrophy | 15 (34%) | 10 (17%) | 11 (17%) | 9 (15%) | 45 (20%) |
Ecchymosis | 4 (9%) | 7 (12%) | 6 (9%) | 4 (7%) | 21 (9%) |
Postinflammatory hyperpigmentation | 5 (11%) | 7 (11%) | 3 (5%) | 0 (0%) | 15 (7%) |
Eczema | 1 (2%) | 8 (13%) | 4 (6%) | 1 (2%) | 14 (6%) |
Healed ulcers | 5 (11%) | 0 (0%) | 2 (3%) | 0 (0%) | 7 (3%) |
Urticaria | 0 (0%) | 3 (5%) | 1 (2%) | 0 (0%) | 4 (2%) |
Necrosis | 0 (0%) | 1 (2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
Varicose veins | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2%) | 1 (0.4%) |
Subcutaneous swelling | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2%) | 1 (0.4%) |